- [Ad hoc-Mitteilung gemäss Art. 53 KR] Veränderungen in der Konzernleitung von Roche
- [Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Jahresergebnis 2022 trotz Rückgang der Nachfrage nach COVID-19-Produkten
- [Annonce événementielle au sens de l’art. 53 RC] Roche affiche de bons résultats pour 2022 en dépit d'une baisse de la demande de produits liés au COVID-19
- European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
- Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
More ▼
Key statistics
On Friday, Roche Holding AG (RO:SWX) closed at 327.20, 3.22% above its 52-week low of 317.00, set on Feb 02, 2023.
52-week range
Markit short selling activity
Open | 318.20 |
---|---|
High | 329.80 |
Low | 318.20 |
Bid | -- |
Offer | -- |
Previous close | 327.20 |
Average volume | 29.00k |
---|---|
Shares outstanding | 809.25m |
Free float | 721.97m |
P/E (TTM) | 18.39 |
Market cap | 233.28bn CHF |
EPS (TTM) | 15.36 CHF |
Annual div (ADY) | 9.50 CHF |
---|---|
Annual div yield (ADY) | 2.90% |
Div ex-date | Mar 17 2022 |
Div pay-date | Mar 21 2022 |
Next div ex-date | Mar 16 2023 |
Next div pay-date | Mar 20 2023 |
Data delayed at least 15 minutes, as of Feb 03 2023 16:35 GMT.
More ▼